Equillium Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Equillium Inc - Expects To Fund Operations Into Q4 2025
Equillium Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease
Brief: Equillium Reports Fourth Quarter and FY 2024 Results
Brief: Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
Brief: Equillium Inc Ono Pharmaceutical Makes Strategic Business Decision To Allow Itolizumab Option To Expire
Brief: Equillium Inc - It Was Temporarily Pausing Enrollment In Its Equator Study
Equillium Inc reports results for the quarter ended in June - Earnings Summary
Equillium Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Equillium Gets Notice From Nasdaq That Co Is Not In Compliance With Nasdaq's Listing Rule 5550(A)(2)
Brief: Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
Brief: Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
Equillium Inc reports results for the quarter ended in March - Earnings Summary
Equillium Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Equillium Announces Positive Topline Data From Type B Portion Of Phase 1b EQUALISE Study Of Itolizumab In Lupus Nephritis
Equillium Inc reports results for the quarter ended in December - Earnings Summary
Equillium Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Equillium Inc Filed Prospectus Supplement With The Securities And Exchange Commission